Receive regular, detailed analysis focused on biotech and healthcare stocks. Since its 2013 separation from Abbott Laboratories (ABT 1.78%), AbbVie's stock has grown more than 160%. The obvious advantages of a "one and done" permanent cure make them potentially very lucrative therapies. Fawad Razaqzada, market analyst for City Index and FOREX.com, commenting to Capital.com, said: As of 30 June, analyst ratings compiled by MarketBeat shared different price targets for Abbvie stock. Refer to our. AbbVie has been increasing its dividend for 51 years. Get short term trading ideas from the MarketBeat Idea Engine. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.12. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions. I had felt this could be an issue for Skyrizi and Rinvoq, given it is rare for a drug to be as dominant as Humira was, but although the level of competition is fierce, both drugs are more than meeting expectations, and with the entire auto-immune market worth as much as $45 - $50bn, it does seem possible that Skyrizi and Rinvoq could one day generate >$20bn revenues between them, as management hopes. The above table shows quarterly and annual product revenues going back to FY20, whilst the last 4 columns show revenue growth percentage between FY20 and FY21, then revenue growth between Q2'21 and Q2'22, the sequential (quarter on quarter) growth, followed by product sales as a percentage of revenues. Gene therapies have been a long time coming, having first been popularized in the early noughties. The companys operations span 20 countries, treating more than 60 million people and 40 conditions annually. The consensus rating was moderate buy based on 16 analysts ratings, with 10 recommending buy, five hold and sell. These are mostly related to the US Food and Drug Administrations (FDA) approval of Abbvies drug Rinvoq for ulcerative colitis and positive top-line results from the Phase 3 induction study U-EXCEL. The company issued revenue guidance of -. Forecasts shouldnt be used as a substitute for your own research. I am not receiving compensation for it (other than from Seeking Alpha). The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. That led to an overall 6% year-on-year gain of 6%, and a 13% sequential gain. The companys original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. This would represent an increase of 1.78%. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. The average ABBVIE INC stock forecast 2023 represents a 1.86% increase from the last price of $153.729995727539. In February, a Phase 3 induction study saw positive top-line results. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. While some of the gains are due to investor perception that it is a strong company, some view ABBV as a defensive stock, with most of the other stocks in the sector also doing well. To be sure, AbbVie is modeling for a tough year in 2023 for the aesthetics market. When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. Although investing in AbbVie isn't riskless, it is advisable based on what we know about the company. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. The difference between trading assets and CFDs. The CEO, speaking at a fireside chat during the conference, commented: we remain well-positioned to absorb the impact from the Humira LOE and quickly return to strong growth starting in 2025. Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. The companys full-year adjusted diluted EPS guidance excluded any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of the year, as both cannot be reliably forecasted. Neuroscience is one of AbbVie's most intriguing divisions and perhaps the hardest to model. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. Zscaler, Inc Plummets, Is It Time To Buy The Dip? The company projects the U.S. toxin market (where Botox is the top product) will decline by mid-single digits. Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. Should I buy or sell AbbVie stock right now? AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. Both Leqembi and Donanemab are potential $5bn - $10bn selling assets, but both drugs still have safety questions to answer and not certain to be made eligible for reimbursement. This could present more profit potential for drugmakers as well as investors. What is the dividend yield for AbbVie? Management has previously stated that it expects total revenues to decline in 2023 following the Humira LOE, followed by a return to growth in 2024, and a "high single digit CAGR" maintained through the remainder of the decade. The company also successfully completed the acquisition of Syndesi Therapeutics SA in March. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. As such, I have decreased my own expectations for 2022 based on simply doubling H1'22 revenues to get a FY22 figure, and downgrading growth expectations to 3% per annum until 2026. Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). I do much more than just articles at Haggerston BioHealth: Members get access to model portfolios, regular updates, a chat room, and more. As we can see, as per management's guidance revenues fall between 2022 and 2023, before recovering and growing in each year after. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive licence to its Humira-related patents in the US, which will begin on 1 July 2023. Noting the stellar earnings reported by the firm in the first quarter, Richard A. Gonzalez, chairman and CEO of AbbVie, said: An overview of the companys net revenue in Q1 shows a major portion of revenue came from its immunology portfolio, which brought in $6.14bn. A major reason behind Abbvies stellar performance amid the ongoing economic crises is the resolution of the companys Humira (adalimumab) litigation with Alvotech in March 2022. I have downgraded my forecasts to 2016 accordingly however to 2% annual growth. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares. All Rights Reserved. These are Immunology, Oncology, Neurology, Virology and Eye Care. 16 analysts have issued 12-month price targets for AbbVie's shares. Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. AbbVie Fair Value Forecast for 2023 - 2025 - 2030 In the last two years, AbbVie's Price has grown, increasing from $91.55 to $130.05 - an increase of 42.06%. You should never invest money you cannot afford to lose. On average, they predict the company's stock price to reach $161.12 in the next year. $163.64. On 14 January 2022, the FDA approved Abbvies arthritis treatment drug, Rinvoq (upadacitinib), for the treatment of adults with moderately to severely active ulcerative colitis. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. The "King Of Quants" sees 10X potential Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. AbbVie has received a consensus rating of Hold. AbbVie updated its FY 2024 earnings guidance on Friday, February, 10th. When looking for ABBV stock forecasts, its important to bear in mind that analysts forecasts can be wrong. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. AbbVie saw a increase in short interest in February. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold, February 24, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com. Skyrizi has also been approved to treat Crohn's Disease, an added bonus and another multi-billion dollar market. Based on earnings estimates, AbbVie will have a dividend payout ratio of 54.11% next year. Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. Wallet Investor suggested that the price could hit $300.386 in June 2027. (ABBV) AbbVie Stock Predictions from the Leading Provider of Short and Long Term Stock Price Forecasts. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.03. What that means is, essentially it will be on formulary with biosimilars, but there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. Shares are consolidating with a buy. AbbVie product revenues by quarter and year since FY20. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. After 2022 Humira's row is shaded yellow to signify patent expiry. Not only do these companies pay handsome dividends, they typically grow revenues every year and generate wide profit margins which leads to share price upside. Finally, AbbVie was able to raise its financial . (my tables and forecasting). Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. I am not receiving compensation for it (other than from Seeking Alpha). The next two approvals - for Navitoclax in Myelofibrosis and Teliso V in non squamous non-small cell lung cancer ("NSCLC") - are anticipated by management in 2024. The current consensus among 24 polled investment analysts is to Buy stock in Abbvie Inc. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. See what's happening in the market right now with MarketBeat's real-time news feed. My No. ABBV-916 is targeting Alzheimer's and it is an anti-amyloid antibody, with a similar mechanism of action ("MoA") to recently approved Leqembi, developed by Biogen (BIIB) / Eisai, and likely soon-to-be approved Donanemab, developed by Eli Lilly. Note that analysts ABBV stock forecasts can be wrong. The pharma industry witnessed solid growth amid the pandemic. Any company is likely to struggle if sales of its best-selling asset begin to decline by ~20% per annum, which is traditionally the rate at which patent expired drugs' sales slip, but when the drug in question accounts for >35% of a company's sales, as Humira does, the situation becomes even more serious. . Retail sales were up but so was inflation which meant more volatility for stocks. American Consumer News, LLC dba MarketBeat 2010-2023. On average, they expect the company's stock price to reach $161.12 in the next twelve months. The division delivered >$1.65bn in sales in Q2'22, up >15% year-on-year, and with Vraylar, Ubrelvy and possibly Qulipta all earmarked for blockbuster sales - $4bn in the case of Vraylar - my forecasting suggests this division could double in size by 2030, from ~$6.6bn revenues generated in FY22, to >$13.5bn by 2030. It should be noted however that, with ~$12bn near-term debt falling due, and long-term debt of ~$61bn - most of it due to the $66bn acquisition of Allergan, completed in 2020, AbbVie has some hefty interest expense payments to make - $15bn between 2022 and 2027, I estimate, and the level of debt makes it tough for the company to invest in M&A deals. AbbVie says it will pay down debt of $4bn in 2023, which will "bring cumulative debt pay down ~$34bn", but the company is heavily reliant on maintaining an investment grade rating. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". My calculation is that Humira revenues in 2023 will be 80% of the 2022 figure, or $16.7bn. Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year Compare Top Brokerages Here. What other stocks do shareholders of AbbVie own? Management initially blamed slow take-up post pandemic for the drug's declining sales, but Gonzalez also told JPM Conference attendees that "new competitive entrants has significantly lowered our sales expectations for Imbruvica". In the U.S. dermatology segment, where approximately 30% of patients exhibit both skin and joint involvement, Skyrizi is already achieving an in-play patient share of nearly 20%. The risks associated with aesthetics are that the industry can be severely buffeted by economic headwinds, as these products are more consumer focused and are often considered an unnecessary expenditure in times of hardship. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each. In 2022, Humira revenues will likely reach $21bn, which will see the drug overtake cholesterol-lowering Lipitor as the best-selling drug of all-time. Move your mouse over a quarter or year to see how estimates have changed over time. If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. What guidance has AbbVie issued on next quarter's earnings? 8.05% (AbbVie data). Multidrug Resistant Bacteria Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2030) Published: March 2, 2023 at 2:55 a.m. ET comments z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. It's hard to argue against Skyrizi and Rinvoq's performance to date, however, and with the total addressable market across all immunology indications likely well in excess of $100bn, I feel fairly comfortable that AbbVie can grow this division's revenues even as the world's biggest ever selling drug exits stage left. Ltd., AbbVie Overseas S. r.l., AbbVie Oy, AbbVie Participaes Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. I am using a weighted average cost of capital of ~10%, which is broadly consistent with the figure I use when modelling for the other 7 members of what I term the "Big 8" US Pharmas - Johnson & Johnson, Eli Lilly, Pfizer, Merck & Co (MRK), Bristol Myers Squibb, Amgen, and Gilead Sciences (GILD) - which helps prove the accuracy of the calculation. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Currently, the company has a "stable" rating, but that must be maintained or investors will perceive the company as unsafe to invest in and that will drag the share price down rapidly. AbbVie is a leader in ESG and sustainability. That was below AbbVie stock analysts' view for $14.16. Receive regular, detailed analysis focused on biotech and healthcare stocks. AbbVie product revenue forecasts to 2030. AbbVie Stock Forecast 2023 $165.00 In the last five quarters, AbbVie's Price Target has risen from $122.84 to $162.12 - a 31.98% increase. Since then, however, the stock price has fallen 18% to. AbbVie does not have the funds to pursue any large M&A deals, but it does not need to either, given the strength of its pipeline and products. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. (844) 978-6257. If you have an ad-blocker enabled you may be blocked from proceeding. (my tables). Aesthetics was propped up by growing sales of Botox - up 12% year-on-year to $678m, but let down by sales of Juvederm, which management put down to lockdown regulations in China, and the "suspension" of operations in Russia. In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. A Warner Bros. I wrote this article myself, and it expresses my own opinions. Epcoritamab alone will not be sufficient to get AbbVie where it wants to be - despite some analysts believing it will be the highest grossing Pharma revenue wise by 2026. In general, it is important to pay attention to trends, both in the overall market and in the specific sector that a company is in. I have no business relationship with any company whose stock is mentioned in this article. The median estimate represents a +5.72% increase from the last price of 156.07. That figure suggests a forward Price to Earnings ("P/E") ratio of ~10x, which is well below the US Big Pharma sector average of ~23x, although it should be noted that the GAAP/non-adjusted EPS may be only significantly lower than the adjusted figure, based on adjusted EPS of $6.52 across H1'22, and GAAP EPS of $3.03 over the same period. As of 2023 February 22, Wednesday current price of ABBV stock is 151.340$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Abbvie stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. AbbVie declared a quarterly dividend on Thursday, February 16th. About the AbbVie, Inc. stock forecast. View our ABBV earnings forecast. I have no business relationship with any company whose stock is mentioned in this article. On average, analysts forecast that ABBV's EPS will be $11.80 for 2023, with the lowest EPS . Factset: FactSet Research Systems Inc.2019. Free Stock Analysis Report: See The True Value of Any Stock, The Best Strategy For Your Small Trading Account. To see all exchange delays and terms of use please see Barchart's disclaimer. Read the conference call transcript. The average price target is $163.64 with a high forecast of $190.00 and a low forecast of $133.00. We continue to anticipate a clearer path to strong sales growth in 2025 with high-single-digit compounded annual growth rate to the end of this decade. target price for AbbVie stock based on DCF / EBITDA multiple analysis (my table and assumptions). AbbVie has 5 focus areas for its research and products. If you have an ad-blocker enabled you may be blocked from proceeding. The company has a robust pipeline of new products that are in some stage of clinical trials. Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. This suggests a possible upside of 3.8% from the stock's current price. call (03) 8658 0539 support.au@capital.com. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S. r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Without the additional patents - >130 in total - Humira would have lost its market exclusivity in 2016, but having eventually lost protection in Europe, which has resulted in a sales decline from $6.3bn in 2018, to ~$2.7bn in 2022, Humira will finally face generic competition in the US from the beginning of this year. These products are not suitable for everyone and you should therefore consider your objectives, financial situation, needs and experience with these products before investing in them. The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. An investment in AbbVie is not without risk, but my contention is that this Pharma is in good hands - CEO Gonzalez has made few mistakes during his near-decade in charge - and will emerge from the Humira LOE a stronger and more diverse company. Richard A. Gonzalez has an approval rating of 88% among the company's employees. I write about Biotech, Pharma and Healthcare stocks and share investment tips. I wrote this article myself, and it expresses my own opinions. In-depth profiles and analysis for 20,000 public companies. View AbbVie's Short Interest. Their ABBV share price forecasts range from $140.00 to $200.00. 164.71 0.00 0.00%. I am not receiving compensation for it (other than from Seeking Alpha). One of the few pain points AbbVie experienced during a year of portfolio wide growth in 2022 was the decline in the revenue contribution from Imbruvica, approved to treat various types of lymphoma. The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. The company reported its first revenue for Botox competitor Daxxify. The average Abbvie stock price prediction forecasts a potential upside of 7.07% from the current ABBV share price of $155.27. Date. Outside of Humira, management does not have to worry about LOEs for any of its other portfolio products before the end of the decade, which is encouraging, however, based on my own projections of how AbbVie will generate its revenues between 2023 and 2030, if management wants to drive a CAGR in the high single digits after 2025, it will need some help from its pipeline - not an area of particular strength for AbbVie. Our first quarter results highlight the diversity of our portfolio and include compelling performance from key growth drivers Skyrizi, Rinvoq, Aesthetics and Neuroscience. That is substantially higher than the 12% CAGR achieved between 2018 - 2022, although that period includes the additional revenues from Allergan. Discovery Company. Fortunately for AbbVie shareholders Gonzalez and his management team have had many more years than expected to prepare for Humira's Loss of Exclusivity ("LOE"), and it has never been the Pharma's ambition to build its business around a single, all-conquering but time-limited drug. AbbVie's Dividend and Valuation. Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar. . ABBV-916 is therefore a real opportunity for AbbVie to develop a more effective and safer drug in the same class and claim a sizeable share of a 6m patient market. For full year 2022, Abbvie predicted the adjusted diluted EPS guidance range at $14.00 to $14.20 and $13.92 to $14.12. I'll also share some a forward income statement and discounted cash flow analysis that suggests the present value of AbbVie shares ought to trade as high as $176, implying that shares are presently discounted by as much as 18% to their true worth. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. AbbVie is led by CEO and Chairman Rick Gonzalez - likely the only Pharma CEO who lacks a college degree - who has successfully defended Humira from generic drug competition by adopting a controversial strategy of continually applying for new patents related to minor changes in manufacturing methods or administration, often referred to as a "patent thicket". First of all, as shown in the table above I forecast product sales out to 2030. I will conclude this analysis by stating that, based on all available information, market headwinds and tailwinds, competitors, and opportunities via its products and pipeline, I still consider AbbVie to be a strong investment opportunity. The official website for the company is www.abbvie.com. We expect proof-of-concept data from roughly a dozen additional early stage oncology opportunities over the next couple of years. Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year and sales will enter a period of terminal decline. How do I arrive at my share price target? See AbbVie Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. In summary, the total revenue increase of just 4% year-on-year in Q2'22 might disappoint a few investors, as might the downgraded guidance, although it is hard to argue that AbbVie is a bad investment when we consider that the Pharma also pays a dividend of $1.41 per quarter, yielding 4% per annum, drove operating earnings of $3.925bn on a GAAP basis, and trades at a >10% discount to my calculated target price. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. 67.71% of the stock of AbbVie is held by institutions. AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Myelofibrosis has proved to be a tricky indication for drug developers and there are no wholly satisfactory solutions on the market at present, therefore if approved I would expect Navitoclax - a drug that AbbVie has been working on for some time - to generate a couple of billion dollars in peak sales. Skyrizi is a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialisation globally.

Late Show With Stephen Colbert Cancelled, Blooket Codes Live Right Now, Articles A